About US
Contact us
-
Novartis forced to face claims it fired employee for raising Gilenya kickback scheme concernsDogged by whistleblowerkickback claims over its multiple sclerosis med Gilenya for years, Novartis has run off a recent string of court wins to escape the allegations. But in one New Jersey suit, Nov2020/4/14
-
Which pharma companies are the most innovative? Roche, AstraZeneca top the listThe continued prosperity of a biopharma company is dependent on its ability to keep churning out breakthrough new drugs and turning them into commercial successes backed by a growing body of clinical2020/4/13
-
Pfizer scores FDA nod for Braftovi duo in colon cancer as investors await more lucrative tripletWhen Pfizer shelled out $11.4 billion for Array BioPharma last year, it pointed to early data showing that Array’s BRAF inhibitor Braftovi, its anti-MEK drug Mektovi and the EGFR blocker Erbitux coul2020/4/13
-
Pfizer, Merck KGaA's Bavencio eyes speedy entry into untapped bladder cancer fieldPfizer and Merck KGaA’s Bavencio is heading toward a piece of the crowded bladder cancer market that it can call its own. The drug hasnabbedthe FDA’s priority review designation as a treatment for bl2020/3/27
-
BMS' Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filingsBristol-Myers Squibb’s Opdivo-Yervoy pairing is getting another shot at the previously untreated non-small cell lung cancer market. Wednesday, the New Jersey drugmaker said regulators in the U.S. and2020/3/27
-
With Kevzara in COVID-19 testing, Sanofi and Regeneron won't divvy up their rightsAs part of CEO Paul Hudson's grand vision at Sanofi, the French drugmaker announced late last year a restructuring of its long-standing antibody partnership with Regeneron. But one of those partnered2020/3/20
-
Roche takes $25M in BARDA backing to accelerate Actemra trial in COVID-19Roche has stepped on the gas in testing Actemra for coronavirus patients, thanks to a little more help from the U.S. government. With $25 million in backing from the U.S. Biomedical Advanced Research2020/3/20
-
Alexion plans phase 2 study of Soliris in COVID-19 in coming days: reportThe race for a COVID-19 therapeutic has attracted many of the biggest names in biopharma, and now Alexion is gettingready to place a bet on its own Soliris,GlobalDatareports. The company, which marke2020/3/13
-
Merck's Keytruda inches toward another biomarker-based OK with latest priority reviewMerck & Co.’s immuno-oncology competitors have tried, so far fruitlessly, to use the investigational biomarker tumor mutational burden to help them win approvals. But regulators apparently like w2020/3/13
-
FiercePharmaAsia—AZ-Daiichi's fast Enhertu nod; Astellas' 2 partnered approvals, CAR-T buyAsian drugmakers had a few busy days before the end of 2019. Daiichi Sankyo and partner AstraZeneca won FDA approval for HER2 antibody-drug conjugate Enhertu four months ahead of schedule. Astellas,w2020/1/3